SIGLEC1 and acute respiratory distress syndrome: Furthermore, the number of patients with mild disease who developed a deterioration to a more severe disease stages was insufficient to answer the question whether CD169/SIGLEC1 may be used as a biomarker to predict the progression to ARDS.